Core Insights - On November 20, several companies disclosed their share repurchase and reduction plans, indicating varying levels of confidence in their stock performance [1] Group 1: Share Repurchase Plans - Eddie Precision plans to repurchase A-shares worth between 100 million to 200 million yuan [2] - Aviation Materials plans to repurchase shares worth between 50 million to 100 million yuan [2] - Changshu Bank's executives plan to increase their holdings by no less than 550,000 shares [2] Group 2: Share Reduction Plans - New Hongze's major shareholder reduced their holdings during a period of abnormal stock fluctuations [2] - General Electric's Singapore company plans to reduce its holdings by no more than 3% in China Xidian [2] - Senior management of Lifespring Pharmaceutical plans to reduce their holdings by no more than 0.0044% [2] - Shareholder Zhoushan Ruihao of Wan Feng plans to reduce holdings by no more than 1.75% [2] - Shareholders of Dongxin plan to collectively reduce holdings by no more than 0.71% [2] - Haigang Group, a shareholder of Hainan Mining, plans to reduce holdings by no more than 0.75% [2] - Actual controller Zhang Guifeng of Fulongma reduced 3.7812 million shares from November 19 to November 20 [2] - Shareholder Dongguan Kechuang Investment Group of Shengyi Electronics plans to reduce holdings by no more than 1% [2] - Shareholder Qinyi Partnership of Yayi Technology plans to reduce holdings by no more than 0.25% [2] - Controlling shareholder Yuansi Industrial of New City plans to reduce holdings by no more than 3% [2] - Controlling shareholder of Kaishan plans to reduce holdings by no more than 1% [2] - The largest shareholder of Tuo Jing Technology, the National Fund, plans to reduce holdings by no more than 3% [2] - Controlling shareholder Li Zheng of Wajinjiao plans to reduce holdings by no more than 3% [2] - Shareholder Shanxi Huaxin Hai of Baose plans to reduce holdings by no more than 1% [2] - Shareholders of Huaya Intelligent plan to collectively reduce holdings by 399.21 million shares, accounting for 2.98% of total share capital [2] - Directors and executives of Changxin Bochuang plan to collectively reduce holdings by no more than 0.05% [2] - Shareholders of Longxun plan to collectively reduce holdings by no more than 2.63% [2] - Some directors and executives of Fulede plan to collectively reduce holdings by no more than 0.0104% [2]

Core Points - The company, Lisheng Pharmaceutical, announced that senior management personnel, Guo Xiaoyan, plans to reduce her holdings in the company by selling up to 11,200 shares within three months after a 15 trading day period from the announcement date [2] Summary by Category Company Announcement - Guo Xiaoyan holds 114,800 shares, representing 0.0446% of the company's total share capital and 0.0448% of the total share capital excluding shares in the repurchase account [2] - The planned reduction in shareholding will not exceed 0.0044% of the total share capital after excluding shares in the repurchase account [2]

Core Viewpoint - The company, Lisheng Pharmaceutical, announced that senior management personnel Guo Xiaoyan plans to reduce holdings of the company's shares through centralized bidding, with a total reduction not exceeding 11,200 shares, which represents a maximum reduction of 0.0044% of the company's total share capital after excluding shares in the repurchase special account [1] Summary by Category - **Company Announcement** - Lisheng Pharmaceutical disclosed that Guo Xiaoyan intends to reduce her shareholding in the company [1] - The planned reduction is limited to a total of 11,200 shares [1] - The reduction accounts for a maximum of 0.0044% of the total share capital after excluding repurchased shares [1]

Core Viewpoint - The company, Lisheng Pharmaceutical (002393.SZ), announced that senior management personnel, Guo Xiaoyan, plans to reduce her shareholding in the company by selling up to 11,200 shares within three months after a 15 trading day period from the announcement date [1] Summary by Categories Shareholding Reduction Plan - Guo Xiaoyan holds 114,800 shares in the company and intends to sell no more than 11,200 shares [1] - The planned reduction represents a maximum of 0.0044% of the company's total share capital after excluding shares in the repurchase special account [1]

Group 1 - Company Lifesun Pharmaceutical (SZ 002393) announced that senior management personnel Guo Xiaoyan plans to reduce her holdings by no more than approximately 11,200 shares within three months after 15 trading days from the announcement date, representing a maximum reduction of 0.0044% of the total share capital excluding shares in the repurchase account [1] - As of the report date, Lifesun Pharmaceutical's market capitalization is 5.4 billion yuan [1] - For the first half of 2025, the revenue composition of Lifesun Pharmaceutical is 100% from the pharmaceutical industry [1]

证券代码：002393 证券简称：力生制药 公告编号：2025-075 天津力生制药股份有限公司 关于公司高级管理人员减持股份预披露公告 本公司高级管理人员郭晓燕女士保证向本公司提供的信息内容真实、准确和完整， 没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 持有天津力生制药股份有限公司（以下简称"公司"）114,800股（占公司总股本比例 0.0446%；占公司剔除回购专用账户中股份数量后的总股本比例0.0448%）的公司高级管 理人员郭晓燕女士，计划在本公告披露之日起15个交易日后的3个月内以集中竞价方式减持 本公司股份合计不超过11,200股，拟减持股份比例不超过公司剔除回购专用账户中股份数 量后总股本的0.0044%。 公司于近日收到高级管理人员郭晓燕女士出具的《股份减持计划申请表》，现将具体 内容公告如下： | 一、拟减持股东的基本情况 | | --- | | | 担任职务 | 持股数量（股） | 占公司总股本 | 占公司剔除回购 专用账户股份数 | 其中持有无限售 | | --- | --- | --- | --- | --- ...

Core Viewpoint - The company, Lisheng Pharmaceutical, announced that its Vice President, Guo Xiaoyan, holds 114,800 shares, accounting for 0.0446% of the total share capital, and plans to reduce holdings by up to 11,200 shares within three months after the announcement [1] Summary by Categories Shareholding Information - Guo Xiaoyan's current shareholding is 114,800 shares, which represents 0.0446% of the total share capital [1] - After excluding repurchased shares, the shareholding percentage is 0.0448% [1] Reduction Plan - The planned reduction involves selling up to 11,200 shares, which constitutes 0.0044% of the total share capital after excluding repurchased shares [1] - The shares to be sold are sourced from the 2022 restricted stock incentive plan [1]

Core Viewpoint - Tianjin Development (00882) announced a new investment agreement involving its indirect non-wholly owned subsidiary, Lifesun Pharmaceutical (002393), which will invest in a fixed-income product through a financial agreement with Xingyin Wealth Management and Industrial Bank [1] Group 1 - Lifesun Pharmaceutical has entered into its eleventh financial agreement with Industrial Bank, committing a principal amount of RMB 30 million, equivalent to approximately HKD 32.82 million [1]

关于使用闲置自有资金进行现金管理的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 证券代码：002393 证券简称：力生制药 公告编号：2025-074 天津力生制药股份有限公司 天津力生制药股份有限公司（以下简称"公司"）于2025年3月19日召开第七届董事会第 五十次会议、2025年4月11日召开2024年度股东大会，审议通过了《关于公司2025年使用 闲置自有资金进行现金管理额度的议案》，同意公司使用额度不超过人民币10亿元闲置自 有资金购买安全性高、流动性好、主要大型商业银行或证券机构发行的短期理财产品，包 括但不限于通过银行、证券等专业理财机构购买的理财产品，期限不超过股东大会批准之 日起12个月，在上述额度及期限范围内资金滚动使用。具体内容详见公司于2025年3月21 日在巨潮资讯网(www.cninfo.com.cn）披露的《关于公司2025年使用闲置自有资金进行现 金管理额度的公告》（公告编号：2025-024）。 一、本次进行现金管理购买理财产品情况 2.理财产品发行人提示了产品包括但不限于信用风险、利率风险、市场风险、流动性风 险 ...

Group 1 - The company held its first meeting of the eighth board of directors on November 13, 2025, with all nine directors present, complying with legal and regulatory requirements [2][3][4] - Zhang Ping was elected as the chairman of the eighth board of directors, with his term starting from the date of the meeting [3][4] - The board established several specialized committees, including the Strategy and Development Committee, Nomination Committee, Compensation and Assessment Committee, and Audit Committee [5][6] Group 2 - The board approved the appointment of Wang Fujun as the general manager, with his term also starting from the date of the meeting [6][7] - Three vice general managers were appointed: Long Changfeng, Liang Jiankang, and Guo Xiaoyan, with their terms aligned with the board's term [7][8] - Wang Jiaying was appointed as the financial director, and Ma Feifei was appointed as the board secretary, both with terms starting from the meeting date [8][9] Group 3 - The board approved the appointment of Zhang Guiling as the head of the Audit and Compliance Department and Liu Zilong as the securities representative, with their terms also starting from the meeting date [10][11] - The board discussed the achievement of the first unlock condition for the 2022 stock incentive plan, allowing 14 individuals to unlock a total of 112,728 shares, representing approximately 0.0438% of the company's total shares [21][34] Group 4 - The eighth board of directors consists of nine members, including five non-independent directors and three independent directors, ensuring compliance with regulatory requirements regarding board composition [39][40] - The company confirmed that all appointed members and directors meet the qualifications and have no disqualifying conditions as per relevant laws and regulations [45][46][47][48][49][50]